Современные возможности антитромботической терапии у пациентов с ишемической болезнью сердца и сахарным диабетом

Почти половина пациентов с ишемической болезнью сердца имеет сопутствующий сахарный диабет, а это, в свою очередь, существенно повышает сердечно-сосудистый риск. Современные подходы к терапии пациентов с ишемической болезнью сердца и коморбидным сахарным диабетом направлены на снижение риска сердечно-сосудистых событий, и основой антитромботической терапии для таких пациентов остается ацетилсалициловая кислота. При применении комбинированной терапии ривароксабаном и ацетилсалициловой кислотой обеспечивается снижение риска значимых событий у разных категорий больных, профиль безопасности двойной антитромботической терапии остается неизменно оптимальным безотносительно к характеру сопутствующих заболеваний.

1. World health organisation. Cardiovascular diseases. https://www.who.int/cardiovascular_diseases/ru/ (28 августа 2020)

2. Nowbar AN, Gitto M, Howard JP, et al. Mortality From Ischemic Heart Disease. Circ Cardiovasc Qual Outcomes. 2019;12(6):e005375. doi:10.1161/CIRCOUTCOMES.118.005375.

3. Epidemiology of IHD. Epidemiology of ischaemic heart disease (IHD) https://www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/Epidemiology-of-IHD (28 august 2020)

4. Kandaswamy E, Zuo L. Recent Advances in Treatment of Coronary Artery Disease: Role of Science and Technology. Int J Mol Sci. 2018;19(2). doi:10.3390/ijms19020424.

5. Оксенойт Г. К., Никитина С. Ю., Агеева Л. И. и др. Здравоохранение в России. 2017: Стат.сб./Росстат. М., 2017, 170 с. ISBN 978-5-89476-448-1.

6. Бойцов С. А., Погосова Н. В., Бубнова М. Г. и др. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;(6):7-122. doi:10.15829/1560-4071-2018-6-7-122.

7. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. doi:10.1093/eurheartj/ehz425.

8. Valgimigli M, Bueno H, Byrne RA, et al; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-60. doi:10.1093/eurheartj/ehx419.

9. Ibanez B, James S, Agewall S, et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. doi:10.1093/eurheartj/ehx393.

10. Aboyans V, Ricco JB, Bartelink MEL, et al; ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816. doi:10.1093/eurheartj/ehx095.

11. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329-39. doi:10.1016/s0140-6736(96)09457-3.

12. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-17. doi:10.1056/NEJMoa060989.

13. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-800. doi:10.1056/NEJMoa1500857.

14. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486.

15. Bosch J, Eikelboom JW, Connolly SJ, et al. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol. 2017;33(8):1027-35. doi:10.1016/j.cjca.2017.06.001.

16. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319-30. doi:10.1056/NEJMoa1709118.

17. Оганов Р. Г., Симаненков В. И., Бакулин И. Г. и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019;18(1):5-66. doi:10.15829/1728-8800-2019-1-5-66.

18. Стабильная ишемическая болезнь сердца. Клинические рекомендации. Министерство здравоохранения Российской Федерации. 2016, ID: КР155. https://legalacts.ru/doc/klinicheskie-rekomendatsii-stabilnaja-ishemicheskaja-bolezn-serdtsa-utv-minzdravom-rossii/

19. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180-9. doi:10.1001/jama.295.2.180.

20. Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17(1):83. doi:10.1186/s12933-018-0728-6.

21. Das SR, Everett BM, Birtcher KK, et al. 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018;72(24):3200-23. doi:10.1016/j.jacc.2018.09.020.

22. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350-7. doi:10.1001/jama.2010.1322.

23. Koskinas KC, Siontis GC, Piccolo R, et al. Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients. Circ Cardiovasc Interv. 2016;9(2):e003255. doi:10.1161/CIRCINTERVENTIONS.115.003255.

24. World Health Organixation. The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (28 August 2020).

25. Bhatt DL, Eikelboom JW, Connolly SJ, et al. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. Circulation. 2020;141(23):1841-54. doi:10.1161/CIRCULATIONAHA.120.046448.

26. Jude EB, Oyibo SO, Chalmers N, et al. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care. 2001;24(8):1433-7. doi:10.2337/diacare.24.8.1433.

27. Kamil S, Sehested TSG, Carlson N, et al. Diabetes and risk of peripheral artery disease in patients undergoing first-time coronary angiography between 2000 and 2012 — a nationwide study. BMC Cardiovasc Disord. 2019;19(1):234. doi:10.1186/s12872-019-1213-1.

28. Frank U, Nikol S, Belch J, et al. ESVM Guideline on peripheral arterial disease. Vasa. 2019;48(Suppl 102):1-79. doi:10.1024/0301-1526/a000834.

29. Бокерия Л.А., Покровский А.В., Акчурин Р.С. и др. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей. Москва, 2019, 89 с. http://www.angiolsurgery.org/library/recommendations/2019/recommendations_LLA_2019.pdf.

30. Thiruvoipati T, Kielhorn CE, Armstrong EJ. Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes. World J Diabetes. 2015;6(7):961-9. doi:10.4239/wjd.v6.i7.961.

31. Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, doubleblind, placebo-controlled trial. Lancet. 2018;391(10117):219-29. doi:10.1016/S0140-6736(17)32409-1.

32. Dumaine RL, Montalescot G, Steg PG, et al. Renal function, atherothrombosis extent, and outcomes in high-risk patients. Am Heart J. 2009;158(1):141-8.e1. doi:10.1016/j.ahj.2009.05.011.

33. Lima EG, Batista DV, Martins EB, et al. Chronic kidney disease and coronary artery disease. Advances in Nephropathy. 2018;193. doi:10.5772/intechopen.79607.

34. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-81. doi:10.1016/S0140-6736(10)60674-5.

35. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41(1):47-55. doi:10.1016/s0735-1097(02)02663-3.

36. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285-95. doi:10.1056/NEJMoa041365.

37. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med. 2002;137(7):563-70. doi:10.7326/0003-4819-137-7-200210010-00007.

38. Więcek A, Wanner C, Caskey FJ, et al. ERA-EDTA Registry: ERA-EDTA Registry Annual Report 2013. Academic Medical Center, Department of Medical Informatics, Amsterdam, The Netherlands, 2015. https://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2013.pdf.

39. Hakeem A, Bhatti S, Karmali KN, et al. Renal function and risk stratification of diabetic and nondiabetic patients undergoing evaluation for coronary artery disease. JACC Cardiovasc Imaging. 2010;3(7):734-45. doi:10.1016/j.jcmg.2010.06.001.

40. Fox KAA, Eikelboom JW, Shestakovska O, et al. Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. J Am Coll Cardiol. 2019;73(18):2243-50. doi:10.1016/j.jacc.2019.02.048.